HOME ABOUT US ADVERTISE SUBSCRIBE SITE MAP HELP CONTACT WORK FOR US  
Tuesday
7 September 2010
Make BTN my HomePage 
 

XENOME LTD STORIES

[14 Results - Showing Results 1 to 14]

Bio People: Xenome, Progen
(Tuesday, 25 May 2010)

FORMER Peplin chief executive officer, director and consultant Michael Aldridge has joined the board of unlisted therapeutics developer Xenome as an executive director.
Full Story...

Capital Briefs: Xenome, CathRx, Cardia Bioplastics, ImpediMed and Immuron
(Thursday, 22 April 2010)

UNLISTED peptide discoverer Xenome has drawn down $4 million of a new $10 million convertible note financing obtained through two investors.
Full Story...

Bio People: Phylogica, Xenome, CathRx
(Thursday, 22 April 2010)

OXFORD BioMedica chief business officer and executive director Nick Woolf has joined Phylogica’s board as a non-executive director.
Full Story...

Pipeline Progress: Benitec, NuSep, Alchemia, Xenome
(Tuesday, 9 March 2010)

THERAPEUTICS developer Benitec and partner CSIRO have requested an oral hearing before the United States Board of Patent Appeals and Interference after the US Patent and Trademark Office answered its appeal against a patent ruling.
Full Story...

Bio People: Freedom Eye, Xenome and ITL
(Thursday, 13 August 2009)

FREEDOM Eye has parted company with chief operating officer Dr David Sparling, announcing yesterday that Sparling had been made redundant as part of the company’s ongoing efforts to conserve cash.
Full Story...

Xenome signs deal with Italian biotech
(Thursday, 13 August 2009)

UNLISTED peptide company Xenome has signed a research collaboration agreement with Italian biotech Axxam to screen Xenome’s synthetic peptide library against a number of unspecified G protein-coupled receptor targets.
Full Story...

Bio Briefs: UNSW, Xenome, Prima and more
(Tuesday, 28 April 2009)

UNIVERSITY of NSW researchers have won $18 million in grant money from the Bill and Melinda Gates Foundation to support a research study into the effectiveness of optimised doses of antiretroviral HIV drug treatment.
Full Story...

Xenome adds new peptides to pipeline
(Thursday, 20 November 2008)

XENOME has expanded its acute pain portfolio with the addition of intellectual property and a number of potential peptide drug candidates from South Australia’s Flinders University.
Full Story...

Xenome kicks off US Phase 2
(Thursday, 25 September 2008)

UNLISTED Queensland biotech Xenome is marching its clinical trial program along at a rapid pace, announcing that the company has begun its Phase 2 trial of pain drug Xen2174 in the US this week.
Full Story...

Positive data for Xenome safety trial
(Tuesday, 26 August 2008)

XENOME painkiller Xen2174 has returned positive safety data in its Phase 1/2 safety trial, according to the company, with Xenome presenting results last week at the 12th World Congress on Pain in Glasgow.
Full Story...

GBS invests confidence in Xenome
(Thursday, 24 July 2008)

GBS Venture Partners will pump $US6 million into Brisbane peptide developer Xenome, lifting the amount the unlisted company has raised in the last 12 months to more than $US16 million.
Full Story...

Bio People: Progen, Xenome, Bone Medical, CollTech
(Tuesday, 3 June 2008)

PROGEN vice-president of research and development Dr Anand Gautam has quit the company only two years after joining the Queensland drug developer. Gautam’s departure will allow former Cellgate executive Dr Laurence Marton to take control of Progen’s early stage clinical pipeline.
Full Story...

US patent win for unlisted Xenome
(Tuesday, 25 March 2008)

UNLISTED Brisbane peptide company Xenome has won a US patent battle over the company’s novel class of norepinephrine transporter (NET) inhibitors. The patent was reissued this week following a ruling on a patent interference process between Xenome and an unnamed US company.
Full Story...

Xenome appoints SAB to drive R&D
(Wednesday, 28 June 2006)

UNLISTED Queensland biotech Xenome has set up a scientific advisory board to oversee its research and development initiatives.
Full Story...